在早期扩散性系统性硬化症中治疗皮肤纤维化的口服葡萄皮质皮质类药物:来自欧洲硬化皮肤病试验和研究小组数据库的目标试验仿真研究
Denis Mongin1, Marco Matucci-Cerinic2, Ulrich A Walker3
1Geneva University Hospitals, Geneva, Switzerland.
Arthritis care & research
|November 14, 2024
概括
在免疫抑制中添加低剂量的口服葡萄糖皮质类药物并没有改善早期扩散性皮肤系统性硬化症 (dcSSc) 的皮肤得分. 这种治疗也没有增加结核性危机的风险,对皮肤纤维化没有显著的益处.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 系统性硬化症是一种慢性自身免疫性疾病,其特征是纤维化.
- 扩散性皮肤系统性硬化 (dcSSc) 涉及广泛的皮肤加厚和内脏器官的参与.
- 早期dcSSc的最佳治疗仍在研究中,有效性和安全性的平衡.
研究的目的:
- 为了确定是否添加口服葡萄糖皮质类药物免疫抑制疗法改善皮肤分数在早期dcSSc.
- 评估组合治疗的安全性,特别是结核病脏危机的风险.
主要方法:
- 使用了模拟随机试验设计,比较了早期dcSSc免疫抑制的患者与或没有低剂量口服皮质糖类药物 (普雷尼松相当于≤20毫克/天).
- 主要结局是12 ± 3个月后修改的罗丹皮肤评分 (mRSS) 的变化.
- 倾向性得分匹配用于控制治疗组和对照组之间的基线差异.
主要成果:
- 总共有208名患者被匹配 (每组104人),具有可比的基线特征.
- 在补充葡萄糖皮质醇的组和对照组 (P = 0.64) 之间没有观察到平均mRSS变化的显著差异.
- 二次性结局,包括渐进性纤维化和硬质皮质危机,也没有显示群体之间的显著差异.
结论:
- 在标准免疫抑制中添加低剂量的口服葡萄糖皮质类药物,对早期dcSSc皮肤纤维化没有显著的益处.
- 研究的葡萄糖皮质激素剂量并没有增加硬化肌性危机的风险,这表明这方面安全性概况有利.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:19Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
222
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
222
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117